ArticlePediatric blood & cancer2019
Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.
Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Histiocytic Sarcoma: A Review and Update.International journal of molecular sciences · 2025Review
- [Immune microenvironment of Langerhans cell histiocytosis: from immune suppression to targeted therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma.Cancer immunology, immunotherapy : CII · 2025Article
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.American journal of hematology · 2024Article
- Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.The clinical respiratory journal · 2024Article
- Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2023Article
- A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.International cancer conference journal · 2022Article
- Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.Molecular and clinical oncology · 2022Article
- Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.Cancer immunology, immunotherapy : CII · 2022Article
- Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.Frontiers in immunology · 2022Article
- Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab.BMJ case reports · 2020Article
- Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.Blood · 2019Review
- PDL1 Expression and Outcomes in Histiocytic Neoplasms.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.